MIT Sloan BioInnovations Conference
February 22, 2013
Boston Marriott Cambridge Hotel
Kendall Square, Cambridge MA

Panel 1: The Future of Pricing and Reimbursement

Heather Steinfield, Moderator

Heather has numerous years of experience providing strategic consulting services to pharmaceutical, biotech and medical device clients.

Heather focuses on activities such as development of global payer value stories and tools for their implementation, moderation of payer/market access advisory boards and internal client workshops, assessment of US public and private payer policy, development of pricing and market access strategies, development of reimbursement strategic plans and specialty distribution programs, HCPCS and CPT coding assessments, and coding applications.

Prior to joining SKP, Heather served as a senior strategist for Quintiles Strategic Research Services, combining brand strategy with Phase IIIb and IV clinical research. At The Lewin Group, she was also a senior manager in the reimbursement strategy group.

Prior to joining Quintiles Strategic Research Services, Heather served as Manager of Reimbursement Programs for PAREXEL's Medical Marketing Services Division. Also with PAREXEL, she served as Market Analyst conducting strategic market assessments and other pre-launch activities.

Heather earned a B.A. in Health and Society from the University of Rochester.

Ira Klein, M.D., Panelist

Ira Klein, MD, MBA is the Chief of Staff to the Chief Medical Officer at Aetna, having joined Aetna in 2006. He has served in a variety of roles at Aetna, and presently leads the Oncology Solutions team, in addition to other enterprise level strategic initiatives. Previously, he was the Medical Director for Quality and Case Management at Bayshore Community Health Services in New Jersey, and before that, the Chief Medical Officer of Elderplan, a Medicare Social HMO that focused on the frail elderly. His early career was as an Assistant Professor of Medicine at Robert Wood Johnson Medical School, teaching and practicing Internal Medicine.

Ted Haack, Panelist

Ted Haack currently heads up the Pricing & Reimbursement team in Pfizer's Primary Care Business Unit.

He started at Pfizer in 2004 in Global Pricing & Reimbursement, responsible for endocrinology, smoking cessation, and thrombosis products, and P&R issues in Europe, Canada, Africa/Middle East and the United States. In 2009, he spent 6 months working in Rwanda as a Pfizer Global Health Fellow and was subsequently appointed Head of Pricing & Reimbursement, Primary Care BU, and was Interim Head of Market Access for PCBU from November 2011 through July 2012. Prior to Pfizer, he spent 7 years at Schering-Plough working with Latin America/Far East finance, Europe/Canada finance, and spent 6 months working in controlling at Essex Pharma, Schering-Plough's German subsidiary.

Ted began his career at Deloitte & Touche in Audit and Advisory Services, including two years in Frankfurt, Germany in the manufacturing practice. He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.

Panel 2: Building Successful Healthcare Start-ups in Today's Challenging Environment

Jonathan Fleming, Moderator

Mr. Fleming is currently a Managing Partner of Oxford Bioscience Partners (OBP), a venture capital firm specializing in life science technology. At OBP, Mr. Fleming is the General Partner of the Korea-Seoul Life Science Fund. Prior to joining OBP, Mr. Fleming was a Founding General Partner of MVP Ventures in Boston, MA. Mr. Fleming also co-founded Medica Venture Partners, an Israeli venture capital firm specializing in early stage healthcare and biotechnology. Mr. Fleming holds a Master's Degree in Public Administration from Princeton University, and a Bachelor of Arts degree from the University of California, Berkeley.

Mr. Fleming is also the director of several companies including Dicerna Pharmaceuticals, Lab Partners, Radius Pharmaceuticals, Greenlight and Railrunner. In addition, Mr. Fleming is also a director of Leerink Swann, a member of the board of the New England Health Initiative, a member of the Scientific Advisory Board at the Massachusetts Life Science Center, and a trustee of the Museum of Science in Boston. Mr. Fleming is also a lecturer at the MIT Sloan School of Business and at Harvard Medical School.

Jose-Carlos Gutierrez-Ramos, Ph.D., Panelist

Dr. José Carlos (JC) Gutiérrez-Ramos is the senior vice-president and head of Biotherapeutic R&D at Pfizer where he leads the discovery and development of novel biologics and small molecules across the Global Pharmacokinetics, Dynamics, and Metabolism, New Biological Entities and Global BioTherapeutic Technologies Research Units.

Prior to joining Pfizer, JC was Senior Vice President and Head of the Immunoinflammation Center for Drug Discovery (iiCEDD) at Glaxo Smith Kline. JC built the iiCEDD as a global group of "drug hunters" that included biologists, chemists, pharmacologists, protein scientists, clinicians and business developers who were responsible for drug discovery and development through Phase IIa (Proof of Concept).

Prior to GSK, JC held positions including the Site Head and Chief Scientific Officer (CSO) at AMGEN Mountain View, the Senior Vice President of R&D at Avidia, where he led a significant effort of novel protein therapeutics for autoimmune disease, CSO of Peptimmune Inc. in Cambridge, MA, where he was responsible for the development of peptide based therapeutics for autoimmune disease, including multiple sclerosis and diabetes, and Vice President, Inflammation at Millennium Pharmaceuticals, where he was responsible for advancing preclinical candidates in Inflammation & Immunology to human trials and advancing compounds (small molecules and antibodies) from discovery through clinical development.

JC was also part of the Faculty at the Genetics department of Harvard Medical School, where he led a major research team at the Center for Blood Research that generated more than 150 peer-reviewed publications. Before coming to the US, he was member of the Basel Institute for Immunology in Basel, Switzerland, and a fellow at the Max-Plank for Immunbiologie in Freiburg, Germany. JC received his master's degree in Chemistry and his Ph.D. in Immunochemistry at the Autónoma University of Madrid, Spain.

Glenn Batchelder, Panelist

Mr. Batchelder is currently the founder and CEO of Civitas Therapeutics, a corporation that focuses on respiratory drug therapy. Prior to Civitas, Mr. Batchelder was the CEO and first employee of BIND Biosciences. Before BIND, Mr. Batchelder was the CEO of Acceleron Pharma, which he brought from a research start-up company to a clinical stage company with a robust preclinical pipeline. Mr. Batchelder has had positions as the Senior Vice President of Operations at Millenium Pharmaceuticals, where he was integral in the launch of Velcade, which now annualizes over $1.5 billion in sales. Mr. Batchelder also serves on the Board of Directors of the Massachusetts Biotechnology Council. He received his Bachelor of Science in Chemical Engineering from Lehigh University.

Jenna Rose, Panelist

Jenna Rose is a Director at Healthbox, a healthcare innovation platform that brings together leading healthcare organizations, investors and entrepreneurs to affect meaningful change in the industry. Jenna leads accelerator operations throughout the U.S. and builds strategy around other growth areas. Before joining Healthbox, Jenna worked on healthcare research, operations and policy in several developing countries, including positions as Senior Research Associate at AID Village Clinics in rural Kenya and Special Coordinator to the Chief Medical Officer of Liberia. She has a Masters of Health Science in Global Disease Epidemiology and Control from the Johns Hopkins School of Public Health and a Bachelors of Arts in Biology and Society with a concentration in International Relations from Cornell University.

Robert Tepper, M.D., Panelist

Dr. Tepper is a co-founder and current Partner of Third Rock Ventures. He has over 25 years of experience building and operating leading R&D operations. Dr. Tepper also assumes active leadership roles in many of Third Rock's portfolio companies often serving as the interim CSO through the first 12-18 months post launch. Prior to Third Rock, Dr. Tepper was the President of R&D at Millenium Pharmaceuticals and also co-founded Cell Genesys/Abgenix. Currently he sits as the Board Member of Alcresta, Allena, bluebird bio, Constellation Pharmaceuticals, and Kala Pharmaceuticals.

Outside of Third Rock, Dr. Tepper is an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital. He is also an advisory board member of several health care institutions including Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. He also serves on the Council of the National Center for the Advancement of Translational Sciences (NCATS) at the National Institutes of Health (NIH).

Panel 3: Healthcare IT: Beyond the Desktop

C. William Hanson III, M.D., Moderator

C. William Hanson, III, MD, Professor of Anesthesiology and Critical Care, Surgery and Internal Medicine at the Hospital of the University of Pennsylvania, is an internist, anesthesiologist and intensivist. He is currently the Chief Medical Information Officer and Vice President of the University of Pennsylvania Health System. Dr. Hanson has extensive experience in medical informatics and was Visiting Professor in the Princeton University Department of Computer Science between 2002 and 2005. Dr. Hanson's anesthetic specialty is cardiac anesthesia (cardiac surgery, thoracic surgery, lung and heart transplantation).

His research using "electronic nose" technology to detect diseases such as pneumonia and sinusitis by breath analysis has been featured in Scientific American. He recently published The Edge of Medicine: The Technology That Will Change Our Lives, a non-fiction book profiling innovations in biotechnology that are changing the delivery of medical care and the ways in which they're altering the human experience.

Also in a recently published, Smart Medicine: How the Changing Role of Doctors Will Revolutionize Health Care, Dr. Hanson reveals the revolutionary changes that will soon be sweeping through the medical community. Dr. Hanson's research has been featured in national and international publications, including Popular Science, U.S. News and World Report, and has been a guest on NPR's Fresh Air as well as television documentaries on the Discovery Channel.

John D. Halamka, M.D., M.S., Panelist

John D. Halamka, MD, MS, is a Professor of Medicine at Harvard Medical School, Chief Information Officer of Beth Israel Deaconess Medical Center, Chairman of the New England Healthcare Exchange Network (NEHEN), co-Chair of the national HIT Standards Committee, co-Chair of the Massachusetts HIT Advisory Committee and a practicing Emergency Physician.

As Chief Information Officer of Beth Israel Deaconess Medical Center, he is responsible for all clinical, financial, administrative and academic information technology serving 3000 doctors, 14000 employees and two million patients. As Chairman of NEHEN he oversees clinical and administrative data exchange in Eastern Massachusetts. As co-Chair of the HIT Standards Committee he facilitates the process of electronic standards harmonization among stakeholders nationwide. As co-Chair of the Massachusetts HIT Advisory Committee, he engages the stakeholders of the Commonwealth to guide the development of a statewide health information exchange.

Scott Andrews, Panelist

Scott Andrews has served as a Vice President of Client Development at athenahealth since 2010. Scott is responsible for managing the performance and satisfaction of athenahealth's client base. Prior to this, Scott served in a variety of leadership roles in finance and operations. Before joining athenahealth in 2000, Scott was a manager at Tufts Health Plan. He was also a manager in the Health Care practice at Ernst & Young and earned a Certified Public Accountant designation. Scott obtained a Bachelor of Science degree in Accounting from St Michael's College in 1990.

Anmol Madan, Ph.D., Panelist

Dr. Madan leads the overall product vision and business strategy at He has extensive research experience in modeling large-scale human behavior data using statistical and pattern recognition methods. His past research has been featured in academic publications in computer science, and featured in popular media like the Economist, BusinessWeek, BBC and CNN. He received his PhD from the Media Lab, at MIT (with Prof. Alex Pentland)

Lauren Fifield, Panelist

As Senior Health Policy Advisor at Practice Fusion, Lauren Fifield manages government relationships and monitors an ever-changing landscape of legislation, regulation, and health industry antics. She advocates for policies that promote the transformation of health care delivery through innovation in health IT and serves on the Executive Committee of the Electronic Health Record Association. Before joining the team, she managed health policy and government affairs for athenahealth, Inc., a provider of web-based software and services to ambulatory providers. Lauren is excited by Practice Fusion's ability to empower independent physicians, everywhere, with equal access to cutting-edge health IT and the opportunity to bring Silicon Valley ideas and her passion for improving healthcare to Washington, DC.

Panel 4: Innovation in Therapeutics: Drugs of the Future

Navjot Singh, Ph.D., Moderator

Dr. Navjot Singh is the leader of the McKinsey Boston Office. His passions include Innovation, R&D and Regulatory related topics. He works with clients across the Healthcare Eco-System working with Pharmaceuticals, Biotechs, Private Equity/Venture Capital Firms, Contract Research Organizations, Health Care Providers and Regulators. He has over 11 years of experience at McKinsey, and prior to joining McKinsey, he was an R&D Leader at General Electric for 6+ years. Dr. Singh received a Ph.D. in Chemical Engineering from the University of Minnesota, and an M.B.A. from Rensselaer Polytechnic Institute. He has a B. Tech from Indian Institute of Technology. He is a co-author of numerous articles and a co-inventor on over 15 patents.

Tim Harris, Ph.D., Panelist

Dr. Tim Harris is a science and business leader with over 30 years of experience guiding and leading laboratory work and scientists in a range of research areas. He is a molecular biologist and biochemist, and currently serves as the SVP for Translational Medicine and Biochemistry at Biogen Idec. He was the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland, which operates The Frederick National Laboratory. He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and founded SGX Pharmaceuticals (formerly Structural Genomix), where he built the company to more than 130 employees, raised $85M in capital, and generated more than $20M in revenue during six years as CEO. Before founding SGX, Dr. Harris was Senior Vice President, Research and Development at Sequana/Axys. He began his career working on animal viruses such as that causing Foot & Mouth Disease and was one of the first molecular biologists at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology.

Anne De Groot, M.D., Panelist

Dr. Anne De Groot is internationally known for her research on the human immune system's response to vaccines and therapeutics. She is founder, CEO and chief scientific officer of EpiVax which develops and employs extensive comprehensive analytical capabilities in the field of computational immunology. Dr. De Groot directs EpiVax's business strategy, marketing, and scientific efforts. She is also a Director of the Institute for Immunology and Informatics at the University of Rhode Island. While serving as a leader both industry and academia, Dr. De Groot also provides clinical care to patients at the Rhode Island TB clinic as well as to patients at Clinica Esperanza/Hope Clinic, a free clinic which Dr. De Groot co-founded. She is also founder and Co-Chief Editor of Infectious Diseases in Corrections report (an on-line journal) and founder and Scientific Director of the GAIA Vaccine Foundation.

De Groot has received uninterrupted federal funding for her research activities through multiple NIH and foundation grants since 1989. She was the recipient of a National Foundation for Infectious Diseases-Eli Lilly Award, two Rhode Island Foundation awards and a Commercial Innovation Award (RI Center for Cellular Medicine). In addition, she was recognized as one of the "Best and the Brightest" in Science and Technology by Esquire Magazine (2003). She has published more than 150 articles and chapters describing the development of epitope-driven vaccines and the application of immunoinformatics tools. In addition to her active research on vaccines for HIV, TB, Tularemia, Smallpox and EBV, she is a pioneer in the field of deimmunizing protein therapeutics.

Prof. Ehud Gazit, Ph.D., Panelist

Prof. Ehud Gazit is the incumbent of the Endowed Chair for Nano-Biology at Tel Aviv University. Since 2012 he also serves as the Chief Scientist of the Israeli Ministry of Science and Technology (MOST).

From 2008-2012 Gazit served as Tel Aviv University Vice President for Research and Development and the Chairman of the board of directors of Ramot Ltd., the technology transfer company of Tel Aviv University. Gazit's technology transfer achievements was acknowledged by inclusion in the 2008 list of 100 Innovations from academic Research to Real-World Application by the Association of University Technology Managers (AUTM) and in a list of 100 Technology Offers stemming from EU Biotechnology RTD results of three Research Framework Programmes (FP5, FP4, and FP3).

Gazit's research focused on the study of biomolecular self-assembly. His work was published in some of the most prestigious academic journals including Science, Nature Nanotechnology, Nature Chemical Biology, and Cell. He is also the inventor of few tens of patent applications. In 2009 he received the Herstin Award for a leading scientist under the age of 44, and elected in 2012 as a fellow of the Royal Society of Chemistry (FRSC). Gazit is or was on the editorial board of several journals including Nanomedicine, PLoS ONE, Amyloid, and Current Chemical Biology.

Gazit holds a B.Sc. from Tel Aviv University and a Ph.D. from Weizmann Institute of Science, for which he received the John F. Kennedy Award in 1996. He has been a faculty member at Tel Aviv University since 2000, after completing his postdoctoral studies at Massachusetts Institute of Technology (MIT) where he also had held a visiting appointment (2002-2011).

Eric Perakslis, Ph.D., Panelist

Food and Drug Administration. Eric is responsible for modernizing and enhancing the IT capabilities as well as the in silico scientific capabilities at FDA. Eric leads a staff of over 500 federal employees and manages an annual technology portfolio of over $0.5 billion. Current program focus includes the technological modernization of the FDA inspectorate, next generation drug and food safety programs and the development of a knowledge ecosystem across FDA. Eric is also the co-chair of the Scientific Computing Architectural Domain at HHS and shares the responsibility for growing and leveraging scientific computing and informatics capabilities across HHS.

Prior to FDA, Eric was Senior Vice President of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D and was a member of the Corporate Office of Science and Technology. During his thirteen years at J&J, Eric also held the posts of Vice President R&D Informatics, Vice President and Chief Information Officer, Director of Research Information Technology as well as assistant Director and Director of Drug Discovery Research prior to his current role. Before joining J&J, Eric was the Group leader of Scientific Computing at ArQule Inc. and he began his professional career with the Army Corps of Engineers.

Eric has a PhD in chemical and biochemical engineering from Drexel University and also holds B.S.Che and M.S. degrees in chemical engineering. Eric's current research interests are enterprise knowledge management, patient stratification, healthcare IT and translational informatics with the specific focus precompetitive data sharing, and open source systems globalization.

Eric is a late-stage kidney cancer survivor and an avid patient advocate. He has served as the Chairman of the Survivor Advisory Board at the Cancer Institute of New Jersey and as the Chief Information Officer of the King Hussein Institute for Biotechnology and Cancer in Amman, Jordan. Eric has also worked extensively with the Lance Armstrong Foundation, the Kidney Cancer Association, the Scientist Survivor program of the American Association for Cancer Research, OneMind4Research and several other top non-profit disease-based organizations to further their domestic and international agendas.

Eric's personal interests include sailboat racing, back-country snowboarding, rock climbing, cycling, running marathons and operating his family vineyard and winery. Eric lives in Doylestown, Bucks County Pennsylvania with his wife Lisa Gail and 11-year old daughter Sammy.